A detailed history of Bank Of America Corp transactions in Liquidia Corp stock. As of the latest transaction made, Bank Of America Corp holds 595,113 shares of LQDA stock, worth $6.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
595,113
Previous 568,775 4.63%
Holding current value
$6.02 Million
Previous $6.83 Million 12.81%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$8.9 - $14.11 $234,408 - $371,629
26,338 Added 4.63%
595,113 $5.95 Million
Q2 2024

Aug 14, 2024

BUY
$11.96 - $15.71 $980,564 - $1.29 Million
81,987 Added 16.84%
568,775 $6.83 Million
Q1 2024

May 15, 2024

BUY
$11.35 - $16.73 $2.47 Million - $3.65 Million
217,900 Added 81.04%
486,788 $7.18 Million
Q4 2023

Feb 14, 2024

BUY
$5.77 - $12.19 $447,209 - $944,798
77,506 Added 40.5%
268,888 $3.23 Million
Q2 2023

Aug 14, 2023

BUY
$6.63 - $9.9 $482,213 - $720,046
72,732 Added 61.3%
191,382 $1.5 Million
Q1 2023

May 12, 2023

SELL
$5.72 - $7.91 $22,022 - $30,453
-3,850 Reduced 3.14%
118,650 $819,000
Q4 2022

Feb 10, 2023

BUY
$4.68 - $6.54 $143,980 - $201,203
30,765 Added 33.54%
122,500 $780,000
Q3 2022

Nov 14, 2022

BUY
$3.73 - $8.39 $311,052 - $699,658
83,392 Added 999.54%
91,735 $499,000
Q2 2022

Aug 12, 2022

SELL
$3.37 - $7.55 $17,288 - $38,731
-5,130 Reduced 38.08%
8,343 $36,000
Q1 2022

May 16, 2022

BUY
$5.14 - $7.38 $60,307 - $86,589
11,733 Added 674.31%
13,473 $97,000
Q4 2021

Feb 08, 2022

SELL
$2.71 - $5.17 $2,829 - $5,397
-1,044 Reduced 37.5%
1,740 $9,000
Q3 2021

Nov 15, 2021

SELL
$2.28 - $2.95 $17,396 - $22,508
-7,630 Reduced 73.27%
2,784 $7,000
Q2 2021

Sep 13, 2021

BUY
$2.51 - $3.11 $26,139 - $32,387
10,414 New
10,414 $30,000

Others Institutions Holding LQDA

About Liquidia Corp


  • Ticker LQDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,362,300
  • Market Cap $651M
  • Description
  • Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...
More about LQDA
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.